Jacob P. Laubach
Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jacob P. Laubach as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:47 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT03702725 · Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple MyelomaAlliance Foundation Trials, LLC. · completed · Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma · study chair
- Ph2NCT02375555 · Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MMDana-Farber Cancer Institute · completed · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:47 UTC. The ranking covers the 200 most relevant of 37 PubMed records, and a shared surname and initials can bring in a namesake. All 37 on PubMed
- Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.N Engl J Med · 2015959 citationsRCR 29.1
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.N Engl J Med · 2016873 citationsRCR 28.4
- Ibrutinib in previously treated Waldenström's macroglobulinemia.N Engl J Med · 2015800 citationsRCR 23.1
- 433 citationsRCR 32.2
- 228 citationsRCR 6.4
- 181 citationsRCR 5.3
- A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.Br J Haematol · 2018147 citationsRCR 5.0
- Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.J Clin Oncol · 2021126 citationsRCR 7.5
- Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.Blood · 201697 citationsRCR 3.0
- Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.Lancet Haematol · 202091 citationsRCR 4.0